Articles from enVVeno Medical Corporation

- Live webcast on Wednesday, June 24th at 2:00 PM ET

IRVINE, CA / ACCESSWIRE / July 8, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that the American Medical Association (AMA) has issued a new, unique CPT III code covering the insertion of a bioprosthetic valve into the femoral vein. The new CPT code, which becomes effective January 1, 2023, will potentially be used by providers performing the VenoValve® procedure on patients across the United States.

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

- Expanding patent portfolio bolsters protection of the Company's lead product -The VenoValve is a potential first-in-class treatment for patients suffering from Chronic Venous Insufficiency (CVI) of the deep veins of the leg - There are currently no effective treatments for patients with deep venous CVI - The VenoValve is currently being evaluated in leading hospitals throughout the U.S. in the ongoing SAVVE U.S pivotal trial IRVINE, CA /

- Ended the Year With $55 Million in Cash Expected To Fund Operations Through the End of 2024 Including Release of Topline Pivotal Trial Data - Nine (9) VenoValve Surgeries Successfully Completed and 16 Clinical Sites Currently Active in Ongoing SAVVE U.S Pivotal Trial - Continued Advancement in Development of Second Device for the Treatment of Venous Disease Expected To Be Unveiled in Mid-2022 IRVINE, CA / ACCESSWIRE / March 28, 2022 /

- Previously announced promising results from the first-in-human study demonstrated sustained safety and effectiveness of the VenoValve at 1-year post-implantation - The VenoValve is currently being evaluated in ongoing SAVVE U.S pivotal trial as a potential treatment for severe deep venous Chronic Venous Insufficiency (CVI) IRVINE, CA / ACCESSWIRE / March 9, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a

- First-in-Human VenoValve recipients continue to benefit from VenoValve at average of 30 months post-surgery - No venous ulcer recurrences, relapses of CVI, or safety issues - Improvements in average Reflux, disease manifestations (VCSS), and pain (VAS) endpoints continue to be encouraging IRVINE, CA / ACCESSWIRE / February 25, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of

- Achievement of Quality Management System certification represents an important step towards commercialization IRVINE, CA / ACCESSWIRE / February 16, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it has received ISO 13485:2016 certification for the Company's Quality Management System (QMS) and its manufacturing facility

Live video webcast presentation on Tuesday, January 25th at 1:00 PM ET IRVINE, CA / ACCESSWIRE / January 20, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno, will present at the Virtual Investor 2022 Top Picks Conference on Tuesday, January 25, 2022 at 1:00 PM ET. As

- Live moderated video webcast discussion with CEO Robert Berman and Marc Glickman, M.D., Senior Vice President and Chief Medical Officer of enVVeno on Tuesday, November 16th at 1:00 PM ET IRVINE, CA / ACCESSWIRE / November 16, 2021 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, CEO and Marc Glickman, M.D.,

- Quarter marked by corporate rebranding and strategic prioritization of development programs - Company executing on SAVVE U.S pivotal trial evaluating lead product, the VenoValve®, as a potential treatment for severe deep venous Chronic Venous Insufficiency (CVI) - Bolstered cash position with recently completed $20 million registered direct offering with leading life sciences investment firm IRVINE, CA / ACCESSWIRE / November 11, 2021 /

- 75 Patient Trial Underway to Evaluate Safety and Efficacy of the VenoValve as a Potential Treatment for Severe Deep Venous Chronic Venous Insufficiency (CVI) - Severe CVI Impacts Approximately 2.4 million U.S. Patients with No Current Effective Treatment Options IRVINE, CA / ACCESSWIRE / October 22, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of

Company Now Trading Under Ticker Symbol "NVNO" IRVINE, CA / ACCESSWIRE / October 1, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, announced today that it has successfully completed its rebranding and that its shares are now trading under the ticker symbol "NVNO" on The Nasdaq Capital Market. The Company was formerly called Hancock Jaffe